SCID (severe combined immunodeficiency) is a group of rare disorders which occurs by mutations in genes involved in the development and function of infection-fighting immune cells. A detailed medical history and physical examination of the child are usually used to diagnose severe combined immunodeficiency (SCID). To help confirm the diagnosis, additional blood tests, including a total blood cell count, may be ordered.SCID (X-linked severe combined immunodeficiency) is an inherited immune system illness that affects virtually exclusively men. Because they lack the required immune cells to fight off some bacteria, viruses, and fungi, boys with X-linked SCID are prone to recurring and persistent illnesses.

The global Severe Combined Immunodeficiency (SCID) Diagnosis market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The global severe combined immunodeficiency (SCID) diagnosis market refers to the market for diagnostic tests used to identify and diagnose infants with SCID, a rare genetic disorder that affects the immune system. SCID is characterized by a severe deficiency in both T cells and B cells, which are crucial for the body’s immune response. Infants with SCID are highly susceptible to severe infections and require early diagnosis and treatment.

The market for SCID diagnosis includes various laboratory-based tests and screening programs. Laboratory-based tests typically involve analyzing blood samples to assess the presence and function of immune cells. Commonly used tests include flow cytometry, T-cell receptor excision circle (TREC) analysis, and next-generation sequencing (NGS) methods to detect gene mutations associated with SCID. Additionally, newborn screening programs using dried blood spot samples have also been implemented in some regions to identify infants with SCID early on.

The global SCID diagnosis market is driven by several factors. One of the primary drivers is the increasing awareness and understanding of SCID among healthcare professionals and the general population. As a result, more infants are being tested for SCID, leading to earlier detection and prompt treatment initiation. Additionally, advancements in genetic testing technologies, such as NGS, have improved the accuracy and efficiency of SCID diagnosis.

Furthermore, government initiatives and newborn screening programs in various countries have contributed to the growth of the SCID diagnosis market. These programs aim to identify infants with SCID shortly after birth, allowing for early intervention and improved outcomes. For example, the implementation of SCID newborn screening programs in several U.S. states has significantly increased the detection of affected infants and facilitated early treatment.

Geographically, North America currently dominates the global SCID diagnosis market. This is primarily due to the higher prevalence of SCID in certain populations, well-established healthcare infrastructure, and the implementation of newborn screening programs. Europe is also a significant market, while other regions, such as Asia-Pacific and Latin America, are expected to witness growth as awareness and healthcare infrastructure continue to improve.

Key players in the global SCID diagnosis market include diagnostic laboratories, healthcare providers, and companies specializing in genetic testing. These companies focus on developing innovative testing methods, improving existing diagnostic tools, and collaborating with healthcare professionals and researchers to advance SCID diagnosis and management.

Overall, the global SCID diagnosis market is expected to witness substantial growth in the coming years, driven by factors such as increased awareness, advancements in genetic testing technologies, and the implementation of newborn screening programs. Early diagnosis and timely intervention are crucial for improving outcomes and quality of life for infants with SCID, emphasizing the importance of continued efforts in SCID diagnosis and management.

This report aims to provide a comprehensive presentation of the global market for Severe Combined Immunodeficiency (SCID) Diagnosis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Severe Combined Immunodeficiency (SCID) Diagnosis.

Report Scope

The Severe Combined Immunodeficiency (SCID) Diagnosis market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Severe Combined Immunodeficiency (SCID) Diagnosis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Severe Combined Immunodeficiency (SCID) Diagnosis companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Severe Combined Immunodeficiency (SCID) Diagnosis Market Report

Report Metric	Details
Report Name	Severe Combined Immunodeficiency (SCID) Diagnosis Market
Segment by Type	TREC Test Complete Blood Count (CBC) Genetic Test Biochemical Test Others
Segment by Application	Hospital Outpatient Center Diagnostic and Research Laboratories Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	ARCHIMEDlife, PerkinElmer, Health Research, Inc, Winfertility, Portea Medical, LaCAR MDX Technologies, Labsystems Diagnostics Oy, Devyser Diagnostics, Revcovi, Leadiant Biosciences
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Severe Combined Immunodeficiency (SCID) Diagnosis companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Severe Combined Immunodeficiency (SCID) Diagnosis Market report?

Ans: The main players in the Severe Combined Immunodeficiency (SCID) Diagnosis Market are ARCHIMEDlife, PerkinElmer, Health Research, Inc, Winfertility, Portea Medical, LaCAR MDX Technologies, Labsystems Diagnostics Oy, Devyser Diagnostics, Revcovi, Leadiant Biosciences

What are the Application segmentation covered in the Severe Combined Immunodeficiency (SCID) Diagnosis Market report?

Ans: The Applications covered in the Severe Combined Immunodeficiency (SCID) Diagnosis Market report are Hospital, Outpatient Center, Diagnostic and Research Laboratories, Others

What are the Type segmentation covered in the Severe Combined Immunodeficiency (SCID) Diagnosis Market report?

Ans: The Types covered in the Severe Combined Immunodeficiency (SCID) Diagnosis Market report are TREC Test, Complete Blood Count (CBC), Genetic Test, Biochemical Test, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 TREC Test

1.2.3 Complete Blood Count (CBC)

1.2.4 Genetic Test

1.2.5 Biochemical Test

1.2.6 Others

1.3 Market by Application

1.3.1 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospital

1.3.3 Outpatient Center

1.3.4 Diagnostic and Research Laboratories

1.3.5 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Perspective (2019-2030)

2.2 Severe Combined Immunodeficiency (SCID) Diagnosis Growth Trends by Region

2.2.1 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Severe Combined Immunodeficiency (SCID) Diagnosis Historic Market Size by Region (2019-2024)

2.2.3 Severe Combined Immunodeficiency (SCID) Diagnosis Forecasted Market Size by Region (2025-2030)

2.3 Severe Combined Immunodeficiency (SCID) Diagnosis Market Dynamics

2.3.1 Severe Combined Immunodeficiency (SCID) Diagnosis Industry Trends

2.3.2 Severe Combined Immunodeficiency (SCID) Diagnosis Market Drivers

2.3.3 Severe Combined Immunodeficiency (SCID) Diagnosis Market Challenges

2.3.4 Severe Combined Immunodeficiency (SCID) Diagnosis Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Severe Combined Immunodeficiency (SCID) Diagnosis Players by Revenue

3.1.1 Global Top Severe Combined Immunodeficiency (SCID) Diagnosis Players by Revenue (2019-2024)

3.1.2 Global Severe Combined Immunodeficiency (SCID) Diagnosis Revenue Market Share by Players (2019-2024)

3.2 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Severe Combined Immunodeficiency (SCID) Diagnosis Revenue

3.4 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Concentration Ratio

3.4.1 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Severe Combined Immunodeficiency (SCID) Diagnosis Revenue in 2023

3.5 Severe Combined Immunodeficiency (SCID) Diagnosis Key Players Head office and Area Served

3.6 Key Players Severe Combined Immunodeficiency (SCID) Diagnosis Product Solution and Service

3.7 Date of Enter into Severe Combined Immunodeficiency (SCID) Diagnosis Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Severe Combined Immunodeficiency (SCID) Diagnosis Breakdown Data by Type

4.1 Global Severe Combined Immunodeficiency (SCID) Diagnosis Historic Market Size by Type (2019-2024)

4.2 Global Severe Combined Immunodeficiency (SCID) Diagnosis Forecasted Market Size by Type (2025-2030)

5 Severe Combined Immunodeficiency (SCID) Diagnosis Breakdown Data by Application

5.1 Global Severe Combined Immunodeficiency (SCID) Diagnosis Historic Market Size by Application (2019-2024)

5.2 Global Severe Combined Immunodeficiency (SCID) Diagnosis Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Size (2019-2030)

6.2 North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2019-2024)

6.4 North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Size (2019-2030)

7.2 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2019-2024)

7.4 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Size (2019-2030)

8.2 Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Region (2019-2024)

8.4 Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Severe Combined Immunodeficiency (SCID) Diagnosis Market Size (2019-2030)

9.2 Latin America Severe Combined Immunodeficiency (SCID) Diagnosis Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2019-2024)

9.4 Latin America Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Size (2019-2030)

10.2 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2019-2024)

10.4 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 ARCHIMEDlife

11.1.1 ARCHIMEDlife Company Detail

11.1.2 ARCHIMEDlife Business Overview

11.1.3 ARCHIMEDlife Severe Combined Immunodeficiency (SCID) Diagnosis Introduction

11.1.4 ARCHIMEDlife Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024)

11.1.5 ARCHIMEDlife Recent Development

11.2 PerkinElmer

11.2.1 PerkinElmer Company Detail

11.2.2 PerkinElmer Business Overview

11.2.3 PerkinElmer Severe Combined Immunodeficiency (SCID) Diagnosis Introduction

11.2.4 PerkinElmer Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024)

11.2.5 PerkinElmer Recent Development

11.3 Health Research, Inc

11.3.1 Health Research, Inc Company Detail

11.3.2 Health Research, Inc Business Overview

11.3.3 Health Research, Inc Severe Combined Immunodeficiency (SCID) Diagnosis Introduction

11.3.4 Health Research, Inc Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024)

11.3.5 Health Research, Inc Recent Development

11.4 Winfertility

11.4.1 Winfertility Company Detail

11.4.2 Winfertility Business Overview

11.4.3 Winfertility Severe Combined Immunodeficiency (SCID) Diagnosis Introduction

11.4.4 Winfertility Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024)

11.4.5 Winfertility Recent Development

11.5 Portea Medical

11.5.1 Portea Medical Company Detail

11.5.2 Portea Medical Business Overview

11.5.3 Portea Medical Severe Combined Immunodeficiency (SCID) Diagnosis Introduction

11.5.4 Portea Medical Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024)

11.5.5 Portea Medical Recent Development

11.6 LaCAR MDX Technologies

11.6.1 LaCAR MDX Technologies Company Detail

11.6.2 LaCAR MDX Technologies Business Overview

11.6.3 LaCAR MDX Technologies Severe Combined Immunodeficiency (SCID) Diagnosis Introduction

11.6.4 LaCAR MDX Technologies Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024)

11.6.5 LaCAR MDX Technologies Recent Development

11.7 Labsystems Diagnostics Oy

11.7.1 Labsystems Diagnostics Oy Company Detail

11.7.2 Labsystems Diagnostics Oy Business Overview

11.7.3 Labsystems Diagnostics Oy Severe Combined Immunodeficiency (SCID) Diagnosis Introduction

11.7.4 Labsystems Diagnostics Oy Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024)

11.7.5 Labsystems Diagnostics Oy Recent Development

11.8 Devyser Diagnostics

11.8.1 Devyser Diagnostics Company Detail

11.8.2 Devyser Diagnostics Business Overview

11.8.3 Devyser Diagnostics Severe Combined Immunodeficiency (SCID) Diagnosis Introduction

11.8.4 Devyser Diagnostics Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024)

11.8.5 Devyser Diagnostics Recent Development

11.9 Revcovi

11.9.1 Revcovi Company Detail

11.9.2 Revcovi Business Overview

11.9.3 Revcovi Severe Combined Immunodeficiency (SCID) Diagnosis Introduction

11.9.4 Revcovi Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024)

11.9.5 Revcovi Recent Development

11.10 Leadiant Biosciences

11.10.1 Leadiant Biosciences Company Detail

11.10.2 Leadiant Biosciences Business Overview

11.10.3 Leadiant Biosciences Severe Combined Immunodeficiency (SCID) Diagnosis Introduction

11.10.4 Leadiant Biosciences Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024)

11.10.5 Leadiant Biosciences Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Labsystems Diagnostics OY

Leadiant Biosciences

Health Research, Inc

LaCAR MDX Technologies

Devyser Diagnostics

Revcovi

List of Tables

Table 1. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of TREC Test

Table 3. Key Players of Complete Blood Count (CBC)

Table 4. Key Players of Genetic Test

Table 5. Key Players of Biochemical Test

Table 6. Key Players of Others

Table 7. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Region (2019-2024) & (US$ Million)

Table 10. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Share by Region (2019-2024)

Table 11. Global Severe Combined Immunodeficiency (SCID) Diagnosis Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 12. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Share by Region (2025-2030)

Table 13. Severe Combined Immunodeficiency (SCID) Diagnosis Market Trends

Table 14. Severe Combined Immunodeficiency (SCID) Diagnosis Market Drivers

Table 15. Severe Combined Immunodeficiency (SCID) Diagnosis Market Challenges

Table 16. Severe Combined Immunodeficiency (SCID) Diagnosis Market Restraints

Table 17. Global Severe Combined Immunodeficiency (SCID) Diagnosis Revenue by Players (2019-2024) & (US$ Million)

Table 18. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Share by Players (2019-2024)

Table 19. Global Top Severe Combined Immunodeficiency (SCID) Diagnosis Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis as of 2023)

Table 20. Ranking of Global Top Severe Combined Immunodeficiency (SCID) Diagnosis Companies by Revenue (US$ Million) in 2023

Table 21. Global 5 Largest Players Market Share by Severe Combined Immunodeficiency (SCID) Diagnosis Revenue (CR5 and HHI) & (2019-2024)

Table 22. Key Players Headquarters and Area Served

Table 23. Key Players Severe Combined Immunodeficiency (SCID) Diagnosis Product Solution and Service

Table 24. Date of Enter into Severe Combined Immunodeficiency (SCID) Diagnosis Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Type (2019-2024) & (US$ Million)

Table 27. Global Severe Combined Immunodeficiency (SCID) Diagnosis Revenue Market Share by Type (2019-2024)

Table 28. Global Severe Combined Immunodeficiency (SCID) Diagnosis Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 29. Global Severe Combined Immunodeficiency (SCID) Diagnosis Revenue Market Share by Type (2025-2030)

Table 30. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Application (2019-2024) & (US$ Million)

Table 31. Global Severe Combined Immunodeficiency (SCID) Diagnosis Revenue Market Share by Application (2019-2024)

Table 32. Global Severe Combined Immunodeficiency (SCID) Diagnosis Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 33. Global Severe Combined Immunodeficiency (SCID) Diagnosis Revenue Market Share by Application (2025-2030)

Table 34. North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2019-2024) & (US$ Million)

Table 36. North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2025-2030) & (US$ Million)

Table 37. Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 38. Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2019-2024) & (US$ Million)

Table 39. Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2025-2030) & (US$ Million)

Table 40. Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 41. Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Region (2019-2024) & (US$ Million)

Table 42. Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Region (2025-2030) & (US$ Million)

Table 43. Latin America Severe Combined Immunodeficiency (SCID) Diagnosis Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Latin America Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2019-2024) & (US$ Million)

Table 45. Latin America Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2025-2030) & (US$ Million)

Table 46. Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 47. Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2019-2024) & (US$ Million)

Table 48. Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2025-2030) & (US$ Million)

Table 49. ARCHIMEDlife Company Detail

Table 50. ARCHIMEDlife Business Overview

Table 51. ARCHIMEDlife Severe Combined Immunodeficiency (SCID) Diagnosis Product

Table 52. ARCHIMEDlife Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024) & (US$ Million)

Table 53. ARCHIMEDlife Recent Development

Table 54. PerkinElmer Company Detail

Table 55. PerkinElmer Business Overview

Table 56. PerkinElmer Severe Combined Immunodeficiency (SCID) Diagnosis Product

Table 57. PerkinElmer Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024) & (US$ Million)

Table 58. PerkinElmer Recent Development

Table 59. Health Research, Inc Company Detail

Table 60. Health Research, Inc Business Overview

Table 61. Health Research, Inc Severe Combined Immunodeficiency (SCID) Diagnosis Product

Table 62. Health Research, Inc Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024) & (US$ Million)

Table 63. Health Research, Inc Recent Development

Table 64. Winfertility Company Detail

Table 65. Winfertility Business Overview

Table 66. Winfertility Severe Combined Immunodeficiency (SCID) Diagnosis Product

Table 67. Winfertility Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024) & (US$ Million)

Table 68. Winfertility Recent Development

Table 69. Portea Medical Company Detail

Table 70. Portea Medical Business Overview

Table 71. Portea Medical Severe Combined Immunodeficiency (SCID) Diagnosis Product

Table 72. Portea Medical Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024) & (US$ Million)

Table 73. Portea Medical Recent Development

Table 74. LaCAR MDX Technologies Company Detail

Table 75. LaCAR MDX Technologies Business Overview

Table 76. LaCAR MDX Technologies Severe Combined Immunodeficiency (SCID) Diagnosis Product

Table 77. LaCAR MDX Technologies Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024) & (US$ Million)

Table 78. LaCAR MDX Technologies Recent Development

Table 79. Labsystems Diagnostics Oy Company Detail

Table 80. Labsystems Diagnostics Oy Business Overview

Table 81. Labsystems Diagnostics Oy Severe Combined Immunodeficiency (SCID) Diagnosis Product

Table 82. Labsystems Diagnostics Oy Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024) & (US$ Million)

Table 83. Labsystems Diagnostics Oy Recent Development

Table 84. Devyser Diagnostics Company Detail

Table 85. Devyser Diagnostics Business Overview

Table 86. Devyser Diagnostics Severe Combined Immunodeficiency (SCID) Diagnosis Product

Table 87. Devyser Diagnostics Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024) & (US$ Million)

Table 88. Devyser Diagnostics Recent Development

Table 89. Revcovi Company Detail

Table 90. Revcovi Business Overview

Table 91. Revcovi Severe Combined Immunodeficiency (SCID) Diagnosis Product

Table 92. Revcovi Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024) & (US$ Million)

Table 93. Revcovi Recent Development

Table 94. Leadiant Biosciences Company Detail

Table 95. Leadiant Biosciences Business Overview

Table 96. Leadiant Biosciences Severe Combined Immunodeficiency (SCID) Diagnosis Product

Table 97. Leadiant Biosciences Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024) & (US$ Million)

Table 98. Leadiant Biosciences Recent Development

Table 99. Research Programs/Design for This Report

Table 100. Key Data Information from Secondary Sources

Table 101. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Share by Type: 2023 VS 2030

Figure 3. TREC Test Features

Figure 4. Complete Blood Count (CBC) Features

Figure 5. Genetic Test Features

Figure 6. Biochemical Test Features

Figure 7. Others Features

Figure 8. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 9. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Share by Application: 2023 VS 2030

Figure 10. Hospital Case Studies

Figure 11. Outpatient Center Case Studies

Figure 12. Diagnostic and Research Laboratories Case Studies

Figure 13. Others Case Studies

Figure 14. Severe Combined Immunodeficiency (SCID) Diagnosis Report Years Considered

Figure 15. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 16. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 17. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Share by Region: 2023 VS 2030

Figure 18. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Share by Players in 2023

Figure 19. Global Top Severe Combined Immunodeficiency (SCID) Diagnosis Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis as of 2023)

Figure 20. The Top 10 and 5 Players Market Share by Severe Combined Immunodeficiency (SCID) Diagnosis Revenue in 2023

Figure 21. North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Share by Country (2019-2030)

Figure 23. United States Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Canada Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Share by Country (2019-2030)

Figure 27. Germany Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. France Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. U.K. Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Italy Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Russia Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Nordic Countries Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Share by Region (2019-2030)

Figure 35. China Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Japan Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. South Korea Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Southeast Asia Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. India Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Australia Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Latin America Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Latin America Severe Combined Immunodeficiency (SCID) Diagnosis Market Share by Country (2019-2030)

Figure 43. Mexico Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Brazil Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Share by Country (2019-2030)

Figure 47. Turkey Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Saudi Arabia Severe Combined Immunodeficiency (SCID) Diagnosis Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. ARCHIMEDlife Revenue Growth Rate in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024)

Figure 50. PerkinElmer Revenue Growth Rate in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024)

Figure 51. Health Research, Inc Revenue Growth Rate in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024)

Figure 52. Winfertility Revenue Growth Rate in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024)

Figure 53. Portea Medical Revenue Growth Rate in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024)

Figure 54. LaCAR MDX Technologies Revenue Growth Rate in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024)

Figure 55. Labsystems Diagnostics Oy Revenue Growth Rate in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024)

Figure 56. Devyser Diagnostics Revenue Growth Rate in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024)

Figure 57. Revcovi Revenue Growth Rate in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024)

Figure 58. Leadiant Biosciences Revenue Growth Rate in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2019-2024)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Nusinersen Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-29F16037

Tue Aug 27 00:00:00 UTC 2024

Add to Cart

Global Schnitzler Syndrome Treatment Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-20K14195

Wed Aug 14 00:00:00 UTC 2024

Add to Cart

Global Human Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Kit Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-10U15263

Mon Aug 05 00:00:00 UTC 2024

Add to Cart

Global Gardner Syndrome Treatment Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-28H13051

Wed Jul 24 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions